Remyelinating Effects Seen With Cladribine in Relapsing Multiple Sclerosis
Data from a small-scale, open-label study of patients with highly active relapsing-remitting multiple sclerosis (RRMS) revealed that nearly one-fifth of all lesions remyelinated over a 2-year period with cladribine (Mavenclad; EMD Serono), an FDA-approved …